Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in clostridium difficile infection

Clinical Infectious Diseases

Volumn 56, Issue 12, 2013, Pages 1713-1721

  El Feghaly, Rana E ^a   Stauber, Jennifer L ^a   Deych, Elena ^a   Gonzalez, Carlos ^a   Tarr, Phillip I ^a,b   Haslam, David B ^a,b  

^a Biostatistical Consulting Center   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; CXCL 5; cytokines; IL 8; inflammation

Indexed keywords

BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CARBAPENEM; CEPHALOSPORIN; CLINDAMYCIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 8; LACTOFERRIN; MACROLIDE; MESSENGER RNA; METRONIDAZOLE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; STEROID; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

CLOSTRIDIUM DIFFICILE; CXCL-5; CYTOKINES; IL-8; INFLAMMATION;

AGED; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CLOSTRIDIUM DIFFICILE; CYTOKINES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MISSOURI; PROSPECTIVE STUDIES; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84878317467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit147     Document Type: Article

References (40)

1. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3:563-78.
2. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-34; quiz 35-6.
3. Dubberke ER, Haslam DB, Lanzas C, et al. The ecology and pathobiolo-gy of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health 2011; 58:4-20.
4. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-9.
5. DuPont HL, Garey K, Caeiro JP, Jiang ZD. New advances in Clostridi-um difficile infection: changing epidemiology, diagnosis, treatment and control. Current Opinion Infect Dis 2008; 21:500-7.
6. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief 124. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville, MD, 2009.
7. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40:1586-90.
8. Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents 2012; 40:1-8.
9. Belmares J, Gerding DN, Tillotson G, Johnson S. Measuring the severity of Clostridium difficile infection: implications for management and drug development. Expert Rev Anti Infect Ther 2008; 6:897-908.
10. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043-6.
11. Fujitani S, George WL, Murthy AR. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011; 32:220-8.
12. Louie TJ, Peppe J, Watt CK, et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43:411-20.
13. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: a severity index for Clostridium difficile infection at the time of admission. J Hosp Infect 2011; 79:151-4.
14. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005; 40:265-72.
15. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38:350-4.
16. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 55:495-501.
17. Sebaihia M, Wren BW, Mullany P, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38:779-86.
18. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-703.
19. Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev 1990; 3:66-98.
20. Hippenstiel S, Soeth S, Kellas B, et al. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood 2000; 95:3044-51.
21. Ishida Y, Maegawa T, Kondo T, et al. Essential involvement of IFN-gamma in Clostridium difficile toxin A-induced enteritis. J Immunol 2004; 172:3018-25.
22. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60(Pt 8):1070-9.
23. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003; 125:413-20.
24. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4:719-22.
25. Wren MW, Kinson R, Sivapalan M, Shemko M, Shetty NR. Detection of Clostridium difficile infection: a suggested laboratory diagnostic algorithm. Br J Biomed Sci 2009; 66:175-9.
26. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991; 174:1355-62.
27. Z'Graggen K, Walz A, Mazzucchelli L, Strieter RM, Mueller C. The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 1997; 113: 808-16.
28. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32:920-4.
29. Wroblewski D, Hannett GE, Bopp DJ, et al. Rapid molecular characterization of Clostridium difficile and assessment of populations of C. difficile in stool specimens. J Clin Microbiol 2009; 47:2142-8.
30. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62.
31. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostrid-ium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2011; CD004610.
32. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-55.
33. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194-201.
34. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008; 46:1493-8.
35. Cloud J, Noddin L, Pressman A, Hu M, Kelly C. Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 2009; 7:868-73 e2.
36. Morgan OW, Rodrigues B, Elston T, et al. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PloS One 2008; 3:e1812.
37. Sirard S, Valiquette L, Fortier LC. Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 2011; 49:4040-6.
38. Walk ST, Micic D, Jain R, et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012; 55:1661-8.
39. Kim H, Kokkotou E, Na X, et al. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21(WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 2005; 129:1875-88.
40. Warny M, Keates AC, Keates S, et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest 2000; 105:1147-56.